Pharma BD Deal Intelligence
Frames the buyout as a strategic expansion into oncology and inflammation, highlighting Calistoga's first-mover clinical validation of PI3K-delta inhibition…
Leerink Swann analyst Joshua Schimmer called CAL-101 'one of the more promising emerging oncology assets.'
Gilead voluntarily withdrew Zydelig's FL and SLL indications in May 2022 after failing to complete required post-marketing confirmatory studies, leaving CLL…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Gilead acquired Calistoga for $375M upfront plus up to $225M in milestones. Lead asset CAL-101 (idelalisib) was an oral PI3K-delta inhibitor in clinical development for B-cell malignancies; later approved as Zydelig in 2014.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Gilead Sciences Inc. / Calistoga Pharmaceuticals, Inc. (this deal) | 2011 | $600M | 35 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. | 2002 | $464M | 96 |
| Gilead Sciences Inc. / CymaBay Therapeutics | 2024 | $4.4B | 76 |
| Gilead Sciences Inc. / Nurix Therapeutics Inc. | 2019 | $2.3B | 69 |
| Gilead Sciences Inc. / Immunomedics Inc. | 2020 | $21.0B | 68 |
| Gilead Sciences Inc. / Kite Pharma, Inc. | 2017 | $11.9B | 67 |
← Browse all deals · How we score deals
More: 2011 deals · Gilead Sciences Inc. deals · Hematology deals